Shark cartilage: An evidence-based systematic review for the natural standard research collaboration

Catherine Ulbricht; Ethan Basch; Ernie Paul Barrette; Stephen Bent; Heather Boon; Paul Graves Hammerness; Michael Smith; David Sollars; Philippe Szapary; Samuel H. Basch; Candy Tsourounis; Dana Hackman

Shark cartilage: An evidence-based systematic review for the natural standard research collaboration

Catherine Ulbricht, Ethan Basch, Ernie Paul Barrette, Stephen Bent, Heather Boon, Paul Graves Hammerness, Michael Smith, David Sollars, Philippe Szapary, Samuel H. Basch, Candy Tsourounis, Dana Hackman

Research output: Contribution to journal › Review article › peer-review

Abstract

Shark cartilage has become one of the most commonly recognized supplements in the United States. Growing interest in the shark cartilage derivative AE-941 (Neovastat, Aeterna Laboratories Inc., Canada) occurred when preclinical studies demonstrated antiangiogenic, antitumor, and antiinflammatory properties. Several clinical trials have been conducted using AE-941, and the US Food and Drug Administration granted orphan drug status to the agent in 2002. However, there is currently insufficient evidence in humans to recommend for or against shark cartilage use for any indication.

Original language	English
Pages (from-to)	99-111
Number of pages	13
Journal	Journal of Cancer Integrative Medicine
Volume	3
Issue number	3
State	Published - 2005
Externally published	Yes

Keywords

AE-941
Cartilage
Haifischknorpel
Houtsmuller Diet
Neovastat
Shark
Shark fin soup
Squalamine
U-955

Cite this

@article{c3d3bf1848c64708b72a05d64a8b7889,

title = "Shark cartilage: An evidence-based systematic review for the natural standard research collaboration",

abstract = "Shark cartilage has become one of the most commonly recognized supplements in the United States. Growing interest in the shark cartilage derivative AE-941 (Neovastat, Aeterna Laboratories Inc., Canada) occurred when preclinical studies demonstrated antiangiogenic, antitumor, and antiinflammatory properties. Several clinical trials have been conducted using AE-941, and the US Food and Drug Administration granted orphan drug status to the agent in 2002. However, there is currently insufficient evidence in humans to recommend for or against shark cartilage use for any indication.",

keywords = "AE-941, Cartilage, Haifischknorpel, Houtsmuller Diet, Neovastat, Shark, Shark fin soup, Squalamine, U-955",

author = "Catherine Ulbricht and Ethan Basch and Barrette, {Ernie Paul} and Stephen Bent and Heather Boon and Hammerness, {Paul Graves} and Michael Smith and David Sollars and Philippe Szapary and Basch, {Samuel H.} and Candy Tsourounis and Dana Hackman",

year = "2005",

language = "English",

volume = "3",

pages = "99--111",

journal = "Journal of Cancer Integrative Medicine",

issn = "1544-6301",

publisher = "Prime National Publishing Corp.",

number = "3",

}

TY - JOUR

T1 - Shark cartilage

T2 - An evidence-based systematic review for the natural standard research collaboration

AU - Ulbricht, Catherine

AU - Basch, Ethan

AU - Barrette, Ernie Paul

AU - Bent, Stephen

AU - Boon, Heather

AU - Hammerness, Paul Graves

AU - Smith, Michael

AU - Sollars, David

AU - Szapary, Philippe

AU - Basch, Samuel H.

AU - Tsourounis, Candy

AU - Hackman, Dana

PY - 2005

Y1 - 2005

N2 - Shark cartilage has become one of the most commonly recognized supplements in the United States. Growing interest in the shark cartilage derivative AE-941 (Neovastat, Aeterna Laboratories Inc., Canada) occurred when preclinical studies demonstrated antiangiogenic, antitumor, and antiinflammatory properties. Several clinical trials have been conducted using AE-941, and the US Food and Drug Administration granted orphan drug status to the agent in 2002. However, there is currently insufficient evidence in humans to recommend for or against shark cartilage use for any indication.

AB - Shark cartilage has become one of the most commonly recognized supplements in the United States. Growing interest in the shark cartilage derivative AE-941 (Neovastat, Aeterna Laboratories Inc., Canada) occurred when preclinical studies demonstrated antiangiogenic, antitumor, and antiinflammatory properties. Several clinical trials have been conducted using AE-941, and the US Food and Drug Administration granted orphan drug status to the agent in 2002. However, there is currently insufficient evidence in humans to recommend for or against shark cartilage use for any indication.

KW - AE-941

KW - Cartilage

KW - Haifischknorpel

KW - Houtsmuller Diet

KW - Neovastat

KW - Shark

KW - Shark fin soup

KW - Squalamine

KW - U-955

UR - http://www.scopus.com/inward/record.url?scp=33644678091&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:33644678091

SN - 1544-6301

VL - 3

SP - 99

EP - 111

JO - Journal of Cancer Integrative Medicine

JF - Journal of Cancer Integrative Medicine

IS - 3

ER -

Shark cartilage: An evidence-based systematic review for the natural standard research collaboration

Abstract

Keywords

Fingerprint

Cite this